Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antiviral activity against HSV-1 infected in African green monkey Vero cells by plaque reduction assay
Assay data:3 Active, 1 Activity ≤ 1 µM, 15 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Antiviral activity against HSV-1 infected in human E6SM cells assessed as inhibition of virus-induced cytopathicity
Assay data:2 Tested
SummaryPubMed Citation
Potency index, ratio of acyclovir EC50 to test compound EC50 for antiviral activity against HSV-1 KOS infected in African green monkey Vero cells assessed as reduction in virus induced cytopathogenicity by plaque reduction assay
Assay data:1 Tested
Antiviral activity against HSV-1 KOS infected in African green monkey Vero cells assessed as reduction in virus induced cytopathogenicity by plaque reduction assay
Antiviral activity against HSV-1 assessed as inhibition of viral growth
Assay data:2 Active, 1 Activity ≤ 1 µM, 5 Tested
Antiviral activity against lethal intracerebral HSV-1 123 infected in po dosed Swiss mouse model assessed as increase in animal survival administered as single double strength loading dose at 7 hrs post-inoculation and single strength dose at 23, 31, 47, 55, 71, 79 hrs post-inoculation and monitored for 21 days
Antiviral activity against lethal systemic HSV-1 123 infected in po dosed Swiss mouse model assessed as increase in animal survival administered as single double strength loading dose at 7 hrs post-inoculation and single strength dose at 23, 31, 47, 55, 71, 79 hrs post-inoculation and monitored for 21 days
Antiviral activity against thymidine kinase positive HSV-1 SC-16 infected in HFF cells assessed as reduction in viral replication incubated for 3 days by crystal violet staining based microplate reader analysis
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Antiviral activity against thymidine kinase positive HSV-1 123 infected in HFF cells assessed as reduction in viral replication incubated for 3 days by crystal violet staining based microplate reader analysis
Antiviral activity against thymidine kinase positive HSV-1 E-377 infected in HFF cells assessed as reduction in viral replication incubated for 3 days by crystal violet staining based microplate reader analysis
Antiviral activity against HSV-1 KOS infected in human HEL 299 cells assessed as inhibition of virus-induced cytopathogenic effect incubated for 3 to 7 days by MTS assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 11 Tested
Antiviral activity against Herpes simplex virus 1 assessed as inhibition rate at 2.5 ug/ml relative to control
Antiviral activity against Herpes simplex virus 1 assessed as inhibition rate at 5 ug/ml relative to control
Antiviral activity against Herpes simplex virus 1 assessed as inhibition rate at 10 ug/ml relative to control
Antiviral activity against Herpes simplex virus 1
Assay data:5 Tested
Antiviral activity against Herpes simplex virus 1 assessed as reduction in number of plaques at 0.12 mg/ml relative to control
Antiviral activity against Human alphaherpesvirus 1 assessed as plaque reduction at 20 mg/ml relative to control
Antiviral activity against Human alphaherpesvirus 1 infected in African green monkey Vero kidney cells assessed as plaque reduction at 80 uM relative to control
Antiviral activity against HSV-1 assessed as inhibition of viral replication at 40 ug
Antiviral activity against HSV-1 assessed as inhibition of viral replication at 20 ug
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on